ANALYST-DOWNGRADE filed Nov 12, 2026 at 13:17 ET
Melius Research cut its price target on NVDA by 41% to $185 and downgraded the stock from Buy to Hold on November 12, 2026, citing a fundamental reassessment of near-term growth prospects. The firm's 54% accuracy on 69 calls and average 5% return place it near the middle of the analyst pack, but the magnitude of the PT cut is the largest among 57 covering analysts. Consensus remains overwhelmingly bullish with 66 of 69 analysts at Buy or Strong Buy, a mean target of $319.99 implying 84% upside from the current $173.73. However, NVDA has seen 9 downgrades in the past 30 days versus 0 upgrades, and the stock is trading 46% below the consensus mean target. EPS revisions over the past 30 days show 7 upward revisions for the +1y period and 2 for the current fiscal year, with no downward revisions, suggesting analysts are still raising long-term estimates even as near-term sentiment sours. Insider selling has been heavy, with EVP Teter Timothy S. selling $6.8M under a 10b5-1 plan and director Mark Stevens selling $300M in open-market trades, creating a bearish cross-signal. With earnings due November 17, this downgrade adds to a growing chorus of caution ahead of the print.